Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01905696 · ClinicalTrials.gov registry record · Early Phase 1
The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia
A Early Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT01905696 is a Early Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 10 participants.
The verdict
NCT01905696, a Early Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Nitric oxide is believed to contribute to regulation of blood flow by its selective binding to circulating hemoglobin (forming S-nitrosohemoglobin, SNO-Hb) and release in a PO2-dependent manner. This study is designed to test that hypothesis by measuring the effect of hypoxia and exercise on forearm blood flow before and after depletion of SNO-Hb using oral N-acetylcysteine.
Interventions
- DRUG Oral N-acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01905696
The ClinicalTrials.gov registry entry for NCT01905696 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral N-acetylcysteine is the first listed.
NCT01905696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01905696 about?
NCT01905696 is a clinical study titled "The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia". Nitric oxide is believed to contribute to regulation of blood flow by its selective binding to circulating hemoglobin (forming S-nitrosohemoglobin, SNO-Hb) and release in a PO2-dependent manner. This study is designed to test that hypothesis by measuring the effect of hypoxia and exercise on forearm...
What is the current status of trial NCT01905696?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2013-03. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01905696?
The interventions under investigation include: Oral N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT01905696?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.